

Alan V Boddy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6664317/publications.pdf>

Version: 2024-02-01

139
papers

4,727
citations

87888

38
h-index

123424

61
g-index

140
all docs

140
docs citations

140
times ranked

5800
citing authors

#	ARTICLE	IF	CITATIONS
1	Physiologically based pharmacokinetic model predictions of inter-ethnic differences in imatinib pharmacokinetics and dosing regimens. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1735-1750.	2.4	13
2	Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 597-611.	1.9	5
3	Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS-CoV-2 Infection: A Case Study With Imatinib. <i>Journal of Clinical Pharmacology</i> , 2022, , .	2.0	2
4	Is there scope for better individualisation of anthracycline cancer chemotherapy?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 295-305.	2.4	24
5	Optimization of a clofarabine based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28133.	1.5	2
6	Wnt receptor gene FZD1 was associated with schizophrenia in genome-wide SNP analysis of the Australian Schizophrenia Research Bank cohort. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 902-908.	2.3	9
7	Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo Disconnect. <i>Pharmaceutical Research</i> , 2020, 37, 128.	3.5	13
8	Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics. <i>Frontiers in Pharmacology</i> , 2020, 10, 1672.	3.5	30
9	Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the "European Paediatric Oncology Off-patents Medicines Consortium" (EPOC) Trial. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020, 45, 413-422.	1.6	7
10	Potential for pharmacokinetic interactions between <i>Schisandra sphenanthera</i> and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically based pharmacokinetic modelling approach. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2080-2094.	2.4	14
11	Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 693-704.	2.3	21
12	Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort. <i>Clinical Pharmacokinetics</i> , 2019, 58, 911-926.	3.5	19
13	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1029-1043.	3.5	6
14	Pharmacokinetics of Anticancer Drugs Used in Treatment of Older Adults With Colorectal Cancer: A Systematic Review. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 553-560.	2.0	4
15	Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 136-146.	2.4	10
16	Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence. <i>European Journal of Cancer</i> , 2018, 91, 56-67.	2.8	8
17	A Strategy to Refine the Phenotyping Approach and Its Implementation to Predict Drug Clearance: A Physiologically Based Pharmacokinetic Simulation Study. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 798-808.	2.5	4
18	The role of solute carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1575-1584.	1.9	3

#	ARTICLE	IF	CITATIONS
19	Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE) Tj ETQq1 110784314rgBT /Ove		
20	Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 68-71.	3.3	8
21	A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1713-1722.	2.4	10
22	A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26351.	1.5	20
23	Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide. <i>European Journal of Cancer</i> , 2017, 71, 15-24.	2.8	8
24	Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 953-972.	3.3	125
25	Towards a Model-Based Dose Recommendation for Doxorubicin in Children. <i>Clinical Pharmacokinetics</i> , 2017, 56, 215-223.	3.5	5
26	Precision dosing of targeted anticancer drugs' challenges in the real world. <i>Translational Cancer Research</i> , 2017, 6, S1500-S1511.	1.0	22
27	Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 209-216.	2.3	21
28	The path to implementation of personalized medicine of aromatase inhibitors in patients with breast cancer. <i>Pharmacogenomics</i> , 2016, 17, 1861-1864.	1.3	0
29	A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2016, 68, 1-10.	2.8	9
30	Plasma Retinol Kinetics and \hat{I}^2 -Carotene Bioefficacy Are Quantified by Model-Based Compartmental Analysis in Healthy Young Adults with Low Vitamin A Stores. <i>Journal of Nutrition</i> , 2016, 146, 2129-2136.	2.9	29
31	High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. <i>International Journal of Cancer</i> , 2016, 138, 206-216.	5.1	45
32	Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 989-998.	2.4	26
33	Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a 'European Pediatric Oncology Off-patents Medicines Consortium' trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1175-1184.	2.3	25
34	A Retinol Isotope Dilution Equation Predicts Both Group and Individual Total Body Vitamin A Stores in Adults Based on Data from an Early Postdosing Blood Sample. <i>Journal of Nutrition</i> , 2016, 146, 2137-2142.	2.9	35
35	Calpain-1 is associated with adverse relapse free survival in breast cancer: a confirmatory study. <i>Histopathology</i> , 2016, 68, 1021-1029.	2.9	10
36	Imagestream detection and characterisation of circulating tumour cells ' A liquid biopsy for hepatocellular carcinoma?. <i>Journal of Hepatology</i> , 2016, 65, 305-313.	3.7	98

#	ARTICLE	IF	CITATIONS
37	The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 851-863.	3.3	2
38	Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer. <i>European Journal of Cancer</i> , 2016, 55, 27-37.	2.8	10
39	Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. <i>British Journal of Cancer</i> , 2016, 114, 723-730.	6.4	132
40	Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma. <i>European Journal of Cancer</i> , 2016, 55, 56-64.	2.8	46
41	Formulation of Biologically-Inspired Silk-Based Drug Carriers for Pulmonary Delivery Targeted for Lung Cancer. <i>Scientific Reports</i> , 2015, 5, 11878.	3.3	46
42	Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1139-1149.	3.5	23
43	A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study. <i>Clinical Cancer Research</i> , 2015, 21, 267-273.	7.0	43
44	Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2735-2743.	4.1	75
45	Sources of preanalytical error in pharmacokinetic analyses – focus on intravenous drug administration and collection of blood samples. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 825-838.	3.3	4
46	Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 667-674.	2.3	32
47	An LC/MS/MS method for stable isotope dilution studies of $\hat{1}^2$ -carotene bioavailability, bioconversion, and vitamin A status in humans. <i>Journal of Lipid Research</i> , 2014, 55, 319-328.	4.2	34
48	Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer. <i>Clinical Pharmacokinetics</i> , 2014, 53, 741-751.	3.5	33
49	Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 749-763.	2.3	35
50	Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. <i>Biochemical Pharmacology</i> , 2013, 85, 29-37.	4.4	32
51	Adaptive Dosing Approaches to the Individualization of 13- <i>cis</i> -Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma. <i>Clinical Cancer Research</i> , 2013, 19, 469-479.	7.0	45
52	Carboplatin Dosing in Infants With Retinoblastoma: A Case for Therapeutic Drug Monitoring. <i>Journal of Clinical Oncology</i> , 2012, 30, 3424-3424.	1.6	5
53	Minimization of the Preanalytical Error in Pharmacokinetic Analyses and Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 460-466.	2.0	9
54	Chemotherapy in newborns and preterm babies. <i>Seminars in Fetal and Neonatal Medicine</i> , 2012, 17, 243-248.	2.3	25

#	ARTICLE	IF	CITATIONS
55	Therapy-induced carboplatinâ€“DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues. <i>Biochemical Pharmacology</i> , 2012, 83, 69-77.	4.4	14
56	Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy. <i>European Journal of Cancer</i> , 2011, 47, 1556-1563.	2.8	19
57	Pharmacogenetics of genes across the doxorubicin pathway. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1201-1210.	3.3	29
58	Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 808-819.	1.5	30
59	Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDPâ€“glucuronosyltransferases. <i>British Journal of Pharmacology</i> , 2011, 162, 989-999.	5.4	14
60	Minimization of the Preanalytical Error in Plasma Samples for Pharmacokinetic Analyses and Therapeutic Drug Monitoring - Using Doxorubicin as an Example. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 766-771.	2.0	16
61	Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 1057-1066.	2.3	17
62	Role of UDP-Glucuronosyltransferase Isoforms in 13-cis Retinoic Acid Metabolism in Humans. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1211-1217.	3.3	15
63	Relevance of Nonsynonymous CYP2C8 Polymorphisms to 13-cis Retinoic Acid and Paclitaxel Hydroxylation. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1261-1266.	3.3	21
64	Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate. <i>European Journal of Cancer</i> , 2010, 46, 1841-1847.	2.8	33
65	Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 3177-3183.	7.0	103
66	Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma. <i>Clinical Cancer Research</i> , 2009, 15, 1241-1249.	7.0	75
67	Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma. <i>Journal of Immunological Methods</i> , 2009, 345, 106-111.	1.4	19
68	Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 749-752.	2.3	17
69	Estimation of renal function and its potential impact on carboplatin dosing in children with cancer. <i>British Journal of Cancer</i> , 2008, 99, 894-899.	6.4	10
70	Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 7917-7923.	7.0	361
71	A Phase I and Pharmacokinetic Study of Ixabepilone in Combination with Carboplatin in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2008, 14, 8288-8294.	7.0	14
72	Population Pharmacokinetic Investigation of Actinomycinâ€“D in Children and Young Adults. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 35-42.	2.0	23

#	ARTICLE	IF	CITATIONS
73	Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo. <i>British Journal of Cancer</i> , 2007, 96, 1675-1683.	6.4	30
74	Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma – a study of the United Kingdom Children's Cancer Study Group. <i>British Journal of Cancer</i> , 2007, 96, 424-431.	6.4	52
75	Adaptive dosing and platinum–DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours. <i>British Journal of Cancer</i> , 2007, 96, 725-731.	6.4	35
76	Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group. <i>Clinical Cancer Research</i> , 2007, 13, 6410-6418.	7.0	101
77	Pharmacokinetic Investigation of Imatinib Using Accelerator Mass Spectrometry in Patients with Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2007, 13, 4164-4169.	7.0	32
78	NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Activity and Expression in Bladder and Ovarian Cancer and Lower NRH:Quinone Oxidoreductase 2 Activity Associated with an NQO2 Exon 3 Single-Nucleotide Polymorphism. <i>Clinical Cancer Research</i> , 2007, 13, 1584-1590.	7.0	40
79	Pharmacokinetics and Pharmacogenetics of 13-cis-Retinoic Acid in the Treatment of Neuroblastoma. <i>Therapie</i> , 2007, 62, 91-93.	1.0	11
80	Dosing of Cancer Patients with Low or Absent Renal Function. <i>Therapie</i> , 2007, 62, 117-120.	1.0	0
81	A study to determine the minimum volume of blood necessary to be discarded from a central venous catheter before a valid sample is obtained in children with cancer. <i>Pediatric Blood and Cancer</i> , 2007, 48, 687-695.	1.5	21
82	Paclitaxel poliglumex. <i>Drugs of the Future</i> , 2007, 32, 0776.	0.1	3
83	Potential clinical impact of taking multiple blood samples for research studies in paediatric oncology: How much do we really know?. <i>Pediatric Blood and Cancer</i> , 2006, 46, 723-727.	1.5	16
84	Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 27-34.	2.4	4
85	Biliary excretion of etoposide in children with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 415-417.	2.3	6
86	An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 197-206.	2.3	3
87	A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules. <i>Clinical Cancer Research</i> , 2005, 11, 7834-7840.	7.0	102
88	Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells. <i>British Journal of Cancer</i> , 2005, 92, 696-704.	6.4	44
89	Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1. <i>Clinical Cancer Research</i> , 2005, 11, 3402-3409.	7.0	103
90	Pharmacokinetics of Dactinomycin in a Pediatric Patient Population: a United Kingdom Children's Cancer Study Group Study. <i>Clinical Cancer Research</i> , 2005, 11, 5893-5899.	7.0	53

#	ARTICLE	IF	CITATIONS
91	Cyclophosphamide Metabolism in Children with Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2004, 10, 455-460.	7.0	46
92	Estimation of glomerular filtration rate in paediatric cancer patients using ⁵¹ Cr-EDTA population pharmacokinetics. <i>British Journal of Cancer</i> , 2004, 90, 60-64.	6.4	29
93	Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 295-300.	2.3	13
94	Chemotherapy individualization. <i>Investigational New Drugs</i> , 2003, 21, 149-156.	2.6	17
95	Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 795, 237-243.	2.3	20
96	2-[¹¹ C]Thymidine Positron Emission Tomography as an Indicator of Thymidylate Synthase Inhibition in Patients Treated With AG337. <i>Journal of the National Cancer Institute</i> , 2003, 95, 675-682.	6.3	67
97	Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules. <i>Annals of Oncology</i> , 2002, 13, 399-402.	1.2	8
98	Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma. <i>Journal of Clinical Oncology</i> , 2002, 20, 3533-3544.	1.6	141
99	Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). <i>European Journal of Cancer</i> , 2002, 38, 1081-1089.	2.8	31
100	Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells. <i>Biochemical Pharmacology</i> , 2002, 63, 207-215.	4.4	32
101	Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide. <i>British Journal of Clinical Pharmacology</i> , 2002, 53, 83-91.	2.4	15
102	All Half-Lives Are Wrong, But Some Half-Lives Are Useful. <i>Clinical Pharmacokinetics</i> , 2001, 40, 237-244.	3.5	5
103	Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 297-303.	1.9	15
104	Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 222-228.	2.3	17
105	Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 15-21.	2.3	6
106	A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. <i>British Journal of Cancer</i> , 2001, 84, 1029-1035.	6.4	55
107	Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 433-441.	2.3	27
108	Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 284-290.	2.3	17

#	ARTICLE	IF	CITATIONS
109	Prospective Validation of Renal Function-Based Carboplatin Dosing in Children With Cancer: A United Kingdom Children's Cancer Study Group Trial. <i>Journal of Clinical Oncology</i> , 2000, 18, 3614-3621.	1.6	60
110	Metabolism and Pharmacokinetics of Oxazaphosphorines. <i>Clinical Pharmacokinetics</i> , 2000, 38, 291-304.	3.5	178
111	Saturable metabolism of continuous high-dose ifosfamide with Mesna and GM-CSF: A pharmacokinetic study in advanced sarcoma patients. <i>Annals of Oncology</i> , 1999, 10, 1087-1094.	1.2	37
112	Cyclophosphamide metabolism in children with Fanconi's anaemia. <i>Bone Marrow Transplantation</i> , 1999, 24, 123-128.	2.4	14
113	Phase I and pharmacokinetic study of d-limonene in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 111-117.	2.3	198
114	RMP-7. <i>CNS Drugs</i> , 1997, 7, 257-263.	5.9	6
115	Cisplatin pharmacokinetics in children with cancer. <i>European Journal of Cancer</i> , 1997, 33, 1823-1828.	2.8	43
116	A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. <i>British Journal of Cancer</i> , 1997, 75, 287-294.	6.4	43
117	Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy. <i>British Journal of Cancer</i> , 1997, 76, 1466-1473.	6.4	20
118	Ifosfamide nephrotoxicity: Limited influence of metabolism and mode of administration during repeated therapy in paediatrics. <i>European Journal of Cancer</i> , 1996, 32, 1179-1184.	2.8	39
119	Population pharmacokinetics of carboplatin in children*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 436-443.	4.7	53
120	A Phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. <i>Investigational New Drugs</i> , 1996, 14, 325-335.	2.6	41
121	Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. <i>European Journal of Cancer</i> , 1995, 31, 69-76.	2.8	39
122	Comparison of continuous infusion and bolus administration of ifosfamide in children. <i>European Journal of Cancer</i> , 1995, 31, 785-790.	2.8	28
123	Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients. <i>European Journal of Cancer</i> , 1995, 31, 1804-1810.	2.8	37
124	The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 53-60.	2.3	58
125	Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. <i>Biochemical Pharmacology</i> , 1994, 47, 1157-1163.	4.4	113
126	Individual Variation in the Activation and Inactivation of Metabolic Pathways of Cyclophosphamide. <i>Journal of the National Cancer Institute</i> , 1992, 84, 1744-1748.	6.3	40

#	ARTICLE	IF	CITATIONS
127	Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 30, 207-211.	2.3	50
128	Comparative anticonvulsant potency and pharmacokinetics of (+)- and (âˆ™)-enantiomers of stiripentol. <i>Epilepsy Research</i> , 1992, 12, 29-36.	1.6	33
129	Combined thin-layer chromatographyâ€™photographyâ€™densitometry for the quantification of ifosfamide and its principal metabolites in urine, cerebrospinal fluid and plasma. <i>Biomedical Applications</i> , 1992, 575, 137-142.	1.7	24
130	Influence of antibiotics on the recovery and kinetics of <i>Saccharomyces boulardii</i> in rats. <i>Pharmaceutical Research</i> , 1991, 08, 796-800.	3.5	40
131	Stereoselectivity in pharmacokinetics: a general theory. <i>Pharmaceutical Research</i> , 1991, 08, 551-556.	3.5	56
132	In vitro and in vivo investigations of dihydropyridine-based chemical delivery systems for anticonvulsants. <i>Pharmaceutical Research</i> , 1991, 08, 690-697.	3.5	15
133	Application of a linear recirculation model to drug targeting. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1991, 19, 355-362.	0.6	7
134	Response to Siegelet al.. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1991, 19, 373-374.	0.6	0
135	Pharmacokinetic Consequences of Product Stereoselectivity in the Metabolism of Nafimidone: Estimation of Fraction Metabolized. <i>Journal of Pharmaceutical Sciences</i> , 1991, 80, 812-814.	3.3	2
136	The use of pharmacokinetic models in the development and evaluation of site-specific drug delivery systems. <i>Pest Management Science</i> , 1990, 30, 91-95.	0.4	0
137	Pharmacokinetic and pharmacodynamic aspects of site-specific drug delivery. <i>Advanced Drug Delivery Reviews</i> , 1989, 3, 155-163.	13.7	11
138	Binding of sulfonamides to carbonic anhydrase: influence on distribution within blood and on pharmacokinetics. <i>Pharmaceutical Research</i> , 1989, 06, 203-209.	3.5	10
139	Efficiency of drug targeting: steady-state considerations using a three-compartment model. <i>Pharmaceutical Research</i> , 1989, 06, 367-372.	3.5	33